Search Results - "Ogboo, Blessing C."

Architecture of the NADPH oxidase family of enzymes by Ogboo, Blessing C., Grabovyy, Uriy V., Maini, Aniket, Scouten, Scott, van der Vliet, Albert, Mattevi, Andrea, Heppner, David E.

“…The NADPH Oxidases (NOX) catalyze the deliberate production of reactive oxygen species (ROS) and are established regulators of redox-dependent processes across…”
Get full text

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors by Wittlinger, Florian, Ogboo, Blessing C., Shevchenko, Ekaterina, Damghani, Tahereh, Pham, Calvin D., Schaeffner, Ilse K., Oligny, Brandon T., Chitnis, Surbhi P., Beyett, Tyler S., Rasch, Alexander, Buckley, Brian, Urul, Daniel A., Shaurova, Tatiana, May, Earl W., Schaefer, Erik M., Eck, Michael J., Hershberger, Pamela A., Poso, Antti, Laufer, Stefan A., Heppner, David E.

“…Bivalent molecules consisting of groups connected through bridging linkers often exhibit strong target binding and unique biological effects. However,…”
Get full text

Demystifying Functional Parameters for Irreversible Enzyme Inhibitors by Heppner, David E, Ogboo, Blessing C, Urul, Daniel A, May, Earl W, Schaefer, Erik M, Murkin, Andrew S, Gehringer, Matthias

Get full text

Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors by Hoyt, Kristopher W, Urul, Daniel A, Ogboo, Blessing C, Wittlinger, Florian, Laufer, Stefan A, Schaefer, Erik M, May, Earl W, Heppner, David E

“…Enzyme inhibitors that form covalent bonds with their targets are being increasingly pursued in drug development. Assessing their biochemical activity relies…”
Get full text

Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448) by Heppner, David E., Wittlinger, Florian, Beyett, Tyler S., Shaurova, Tatiana, Urul, Daniel A., Buckley, Brian, Pham, Calvin D., Schaeffner, Ilse K., Yang, Bo, Ogboo, Blessing C., May, Earl W., Schaefer, Erik M., Eck, Michael J., Laufer, Stefan A., Hershberger, Pamela A.

“…Lazertinib (YH25448) is a novel third-generation tyrosine kinase inhibitor (TKI) developed as a treatment for EGFR mutant non-small cell lung cancer. To better…”
Get full text

Design and characterization of NOX-targeting compounds for improved understanding of covalent inhibitors by Heppner, David E., Ogboo, Blessing C., Patel, Kishan B., Reis, Joana, Massari, Marta, Marchese, Sara, Mattevi, Andrea

Get full text

Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors: Miniperspective by Hoyt, Kristopher W., Urul, Daniel A., Ogboo, Blessing C., Wittlinger, Florian, Laufer, Stefan A., Schaefer, Erik M., May, Earl W., Heppner, David E.

“…Enzyme inhibitors that form covalent bonds with their targets are being increasingly pursued in drug development. Assessing their biochemical activity relies…”
Get full text